No Data
No Data
KEYMED BIO-B: 2024 INTERIM REPORT
[Brokerage Focus] Hua Yuan Securities maintains a "buy" rating on Connoah (02162), pointing out that its R&D pipeline is progressing smoothly.
Jingu Wealth News | Huayuan Securities issued a research report, stating that on September 12, Kangnuoya (02162) officially obtained market approval for the self-developed Class 1 new drug Kangyueda (dupilumab injection), used to treat moderate to severe atopic dermatitis in adults. It is the first domestically approved and second globally approved IL-4Rα antibody drug, filling the gap in the field of domestic atopic dermatitis biologics. The report indicates: 1) Clinical data shows that patients' itching symptoms improve rapidly after the first dose of dupilumab; after two weeks of treatment, the skin lesions all over the body significantly improve; after 52 weeks of treatment, reaching EASI-75.
Hong Kong stocks have experienced abnormal movement, with the concept of innovative drugs leading the way. The National Medical Products Administration has accelerated the approval of clinical pharmaceuticals, and many biotech companies have turned losses
Innovative drug concept has the highest increase. As of the time of writing, Akeso (01541) rose 60.42%, to HKD 6.16; Innocare (09926) rose 12.17%, to HKD 63.15; Innocare (09969) rose 6.19%, to HKD 5.83; Kanoa-B (02162) rose 5.56%, to HKD 39.85.
HK Stock Market News: Kangnova-B (02162) surged over 5% in the morning. CM310 adult AD indications approved. Two other indications have already submitted NDA.
Konoa-B (02162) rose more than 5% in the morning. As of the time of writing, it has risen 3.97% to HKD 39.25, with a turnover of HKD 81.3695 million.
gtja: Maintain a "shareholding" rating for Kangnaoya-B(02162). The first domestically produced IL-4R monoclonal antibody Kangyueda has been approved.
gtja maintains the revenue forecast for Kangnaoya-B (02162) from 2025 to 2026 at 0.526/1.441 billion yuan.
Express News | Stapokibart Was Granted Marketing Approval From National Medical Products Administration for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
No Data
No Data